Regenerative Therapies Library

Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.

All Library Articles Presentations Spotlights News

Showing 121–144 of 152

Longevity.TechnologyFeb 5, 2026

Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence

Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.

Longevity.TechnologyFeb 11, 2026

Pandorum lands $18m to advance ‘programmable regenerative medicine’

Pandorum Technologies closed an $18 million Series B round to advance exosome-based therapies designed to modulate tissue state away from inflammatory and fibrotic conditions toward functional recovery. The platform targets corneal opacity initially, with applications potentially extending across multiple organs affected by inflammatory and degenerative disease.

Wiley Aging CellApr 9, 2026

Single‐Cell Profiling Reveals RAB13+ Endothelial Cells and Profibrotic Mesenchymal Cells in Aged Human Bone Marrow

Single-cell analysis reveals that aging bone marrow undergoes distinct cellular remodeling: endothelial cells develop prothrombotic and mitochondrial dysfunction, while a novel RAB13+ arterial endothelial subset emerges alongside expansion of profibrotic mesenchymal cells. These cellular shifts directly impair the marrow's capacity to support healthy blood cell production and tissue maintenance, establishing specific molecular targets for intervention.

LT WireMar 12, 2026

Celularity secures $35m license deal to back longevity strategy

Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.

Neuroscience NewsMar 20, 2026

RNA Recycling Extends Lifespan

RNASEK, an enzyme that degrades circular RNA accumulation in cells, extends lifespan in model organisms by removing a form of molecular waste that accelerates aging. This identifies a specific degradation pathway central to cellular longevity.

Longevity.TechnologyMar 23, 2026

Unlimited Bio registers dual gene therapy trial

Unlimited Bio initiated a Phase 1/2a trial combining AAV9-Follistatin and VEGF plasmid gene therapies to address age-related muscle decline, marking the first registered clinical study to combine these two approaches. The dual-therapy strategy targets both muscle growth signaling and vascular support, with safety and functional outcomes tracked over 12 months in adults aged 45 to 75.

LT WireMar 14, 2026

Pretzel Therapeutics presents PX578 data supporting POLG disease treatment

PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.

Longevity.TechnologyMar 16, 2026

Engineering longevity with the ZEUGMA hyperbaric chamber

Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.

LT WireApr 27, 2026

Nuritas brings PeptiStrong clinical momentum to Vitafoods

Nuritas is conducting a 30-day randomized controlled trial comparing PeptiStrong (a fava bean-derived peptide) plus whey protein against whey protein alone in adults aged 60–85, with grip strength as the primary outcome and secondary measures including gait speed, balance, and inflammatory markers. The trial addresses a direct mechanism relevant to aging: preserving muscle function and mass in older populations.

Nature AgingFeb 12, 2026

Clonal hematopoiesis boosts response to immune checkpoint therapy

Clonal hematopoiesis—the age-related expansion of mutant blood cell populations—enhances response to immune checkpoint inhibitors in cancer patients. This unexpected finding reframes a hallmark of aging as potentially protective in the context of immunotherapy, with implications for how we interpret immune aging and treatment efficacy.

Nature AgingMar 31, 2026

Multiomic single-cell perturbation screens reveal critical lncRNA regulators of senescence

A systematic screen of 32 aging-associated long non-coding RNAs identified HOTAIRM1 as a critical regulator of DNA repair pathways, with restoration of HOTAIRM1 in aged mouse lungs reducing fibrosis. This work establishes lncRNA regulation as a targetable mechanism in cellular senescence.

Longevity.TechnologyMar 2, 2026

Japanese startup makes hair follicle regeneration breakthrough

OrganTech has identified a three-cell configuration—including a previously uncharacterized mesenchymal cell type—capable of regenerating fully functional hair follicles that maintain cycling and production in vivo. This work establishes a cellular blueprint for hair follicle regeneration and suggests broader applications for complex tissue reconstruction.

Wiley Aging CellMar 30, 2026

Autophagy‐Independent Function of ATG‐18 Is Essential for Gonadal Longevity in Caenorhabditis elegans

ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.

Longevity.TechnologyMar 2, 2026

Youthful blood proteins found in Swiss centenarians

The SWISS100 study reveals that centenarians maintain blood protein profiles resembling those of much younger adults, with notably lower oxidative stress and finely balanced metabolic systems. This molecular signature suggests that exceptional longevity correlates with sustained cellular integrity rather than accelerated compensatory mechanisms, offering a model for understanding how aging can be slowed at the fundamental biological level.

Longevity.TechnologyApr 14, 2026

FDA fast-tracks United Therapeutics’ bioengineered liver tech

United Therapeutics' bioengineered liver system, miroliverELAP, has received FDA Regenerative Medicine Advanced Therapy designation, accelerating its development as a bridge therapy for acute liver failure patients. The technology uses a decellularized pig liver scaffold seeded with human cells to provide extracorporeal organ support, potentially improving survival in the 30% of patients ineligible for or unable to access transplantation in time.

Longevity.TechnologyApr 3, 2026

Designs for Health launches NeuroCalm Peptide for gut-brain support

Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.

LT WireMar 18, 2026

Cognition Therapeutics reports Zervimesine slows NPI decline in DLB

Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.

Nature AgingMar 3, 2026

Multi-tissue transcriptomic aging atlas reveals predictive aging biomarkers in the killifish

Researchers created a multi-tissue transcriptomic atlas across thirteen tissues in African turquoise killifish at six life stages, identifying molecular patterns of aging that vary by tissue type and sex. This resource establishes predictive biomarkers for aging dynamics and demonstrates how systemic and local factors drive age-related changes across the organism.

Longevity.TechnologyMar 9, 2026

Transposon’s $22m ARPA-H award to test aging-fighting drug

Transposon Therapeutics received a $22 million ARPA-H grant to study TPN-101, a drug designed to inhibit LINE-1 retrotransposon activity and slow fundamental aging processes rather than treat individual diseases. The approach targets age-related inflammation driven by DNA elements that become dysregulated with age, potentially extending healthspan across multiple conditions simultaneously.

Wiley Aging CellApr 25, 2026

Aging‐Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment

In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.

Peter Attia MDJun 6, 2026

Gene therapy PCSK9: Atherosclerosis reversal, not management

A gene therapy targeting PCSK9 demonstrates sustained LDL reduction and early regression of atherosclerotic plaques in trial participants. This approach addresses a primary driver of cardiovascular disease progression, potentially shifting treatment from symptom management to causative intervention.

Longevity.TechnologyApr 1, 2026

20/20 BioLabs expands longevity test with kidney risk tech

20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.

LT WireFeb 4, 2026

Acorn Biolabs treats first patients in randomized hair regeneration trial

Acorn Biolabs has initiated a randomized, controlled trial of YOU, an autologous secretome derived from hair follicle stem cells, to treat androgenic alopecia. The study will measure changes in hair density, thickness, and patient outcomes against placebo, establishing whether personalized regenerative approaches offer clinically meaningful advantages over existing pharmacologic treatments.

LT WireFeb 7, 2026

PrimeGen US to merge with DT Cloud Star in $1.5B SPAC deal

PrimeGen US, a regenerative medicine company developing stem cell and exosome therapies, is merging with a SPAC at a $1.5 billion valuation to advance clinical trials for acute liver injury and related conditions. The capital infusion targets acceleration of regulatory pathways and commercialization of cell-based treatments grounded in two decades of proprietary stem cell research.

Biological EDGE

Biohacking Starts With NO